Savara Inc. faces securities lawsuit
Analysis based on 6 articles · First reported Oct 06, 2025 · Last updated Nov 06, 2025
The class action lawsuit against Savara Inc. is likely to negatively impact its stock price and investor confidence due to allegations of securities fraud. The delay in regulatory approval for MOLBREEVI BLA could also lead to a need for Savara Inc. to raise additional capital, further affecting its financial standing.
Levi & Korsinsky, LLP has initiated a class action securities lawsuit against Savara Inc. on behalf of investors who suffered losses between March 4, 2024, and May 23, 2025. The lawsuit alleges that Savara Inc. made false and misleading statements and/or concealed information regarding its MOLBREEVI BLA, a treatment for pulmonary alveolar proteinosis. Specifically, the complaint claims that MOLBREEVI BLA lacked sufficient information concerning its chemistry, manufacturing, and controls, making United States — Food and Drug Administration approval unlikely in its current form. This delay in regulatory approval increased the likelihood that Savara Inc. would need to raise additional capital, contrary to its representations to investors.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard